Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
M. Faehling
J. Achenbach
P. Staib
U. Steffen
H. W. Tessen
V. E. Gaillard
W. Brugger
机构：
[1] Esslingen Hospital,Clinic for Cardiology und Pneumology
[2] Lung Clinic Lostau,Department of Pulmonary Diseases and Thoracic Oncology
[3] St. Antonius Hospital,Clinic for Hematology and Oncology
[4] Pneumonology,Hematology/Oncology, Schwarzwald Baar Clinic, Acad. Teaching Hospital
[5] Private Practice,undefined
[6] Oncology/Hematology,undefined
[7] Oncological Cooperation Harz,undefined
[8] Roche Pharma AG,undefined
[9] Medical Affairs,undefined
[10] University of Freiburg,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2018年 / 144卷
关键词：
Non-small cell lung cancer; Erlotinib maintenance therapy; Non-interventional study; EGFR; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1375 / 1383
页数：8
相关论文
共 50 条
  • [21] Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?
    Nooshin Hashemi-Sadraei
    Nathan A. Pennell
    Current Treatment Options in Oncology, 2012, 13 : 478 - 490
  • [22] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [23] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study
    Choi, Dae Ro
    Lee, Dae Ho
    Choi, Chang-Min
    Kim, Sang-We
    Suh, Cheolwon
    Lee, Jung-Shin
    ANTICANCER RESEARCH, 2011, 31 (10) : 3457 - 3462
  • [24] Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline
    Chu, Q
    Vincent, M
    Logan, D
    Mackay, JA
    Evans, WK
    LUNG CANCER, 2005, 50 (03) : 355 - 374
  • [25] Erlotinib as 1st-line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Merimsky, O.
    Cheng, C.
    Reck, M.
    Au, S.
    von Pawel, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsh, Vera
    Owen, Scott
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S584 - S584
  • [27] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
    Ahn, Hee Kyung
    Kim, Young Saing
    Kim, Eun Young
    Kyung, Sun Young
    Kang, Shin Myung
    Cho, Eun Kyung
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
  • [28] COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN
    Castro de Carpeno, J.
    Castro-Gomez, A. J.
    Walzer, S.
    Ray, J.
    VALUE IN HEALTH, 2010, 13 (07) : A259 - A259
  • [29] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
    Andric, Z. G.
    Galffy, G.
    Cobo Dols, M.
    Szima, B.
    Stojanovic, G.
    Petrovic, M. D.
    Felip Font, E.
    Vicente Baz, D.
    Ponce Aix, S.
    Juan-Vidal, O.
    Tehenes, S.
    Szalai, Z.
    Losonczy, G.
    Calles Blanco, A.
    Bernabe, R.
    Duecker, K.
    Zhou, D.
    Schroeder, A.
    Guezel, G.
    Ciardiello, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S754
  • [30] Costs associated with neutropenia in elderly patients treated first-line for advanced non-small cell lung cancer (NSCLC)
    Stokes, M. E.
    Muehlenbein, C. E.
    Marciniak, M. D.
    Faries, D.
    Motabar, S.
    Buesching, D. P.
    Gillespie, T. W.
    Lipscomb, J.
    Knopf, K. B.
    VALUE IN HEALTH, 2008, 11 (03) : A10 - A10
12345